SPD-304 is a selective inhibitor of tumor necrosis factor-alpha (TNF-α), disrupting TNF-α trimerization and blocking its interaction with receptors; it inhibits the binding of TNF-α to receptor 1 with an IC50 of 22 µM in vitro; SPD-304 (2 µM) significantly rescues hepatic stellate cell (HSC) survivability, reduces lipid hydroperoxide production, and increases intracellular glutathione (GSH); co-treatment with geldanamycin (GA, 75 µM) and SPD-304 (2 µM) downregulates TRADD by nearly 2-fold and p-RIP3 by 1.4-fold compared to GA alone, and promotes caspase-8 activation; however, SPD-304 is not suitable for in vivo use due to its high toxicity.